Cyanotech(CYAN) - 2023 Q4 - Annual Report

Sales and Revenue - Hawaiian Spirulina Pacifica® accounted for approximately 36% of the company's net sales for the fiscal year ended March 31, 2023[140] - Total contract services revenue represented approximately 3% of net sales for the fiscal year ended March 31, 2023[143] - The company began offering R&D services to third parties in fiscal 2023 due to excess production capacity[127] Production and Technology - The company has been producing Hawaiian Spirulina Pacifica® since 1984, emphasizing its long-standing market presence[140] - The company relies on proprietary production and harvesting technologies to optimize microalgae cultivation[123] - The company has implemented water savings strategies to mitigate challenges related to water supply and pricing, which could impact operations[149] Competition and Workforce - The company faces competition from larger firms with greater resources in the dietary supplement products industry[138] - The company has experienced labor shortages post-COVID-19, affecting its ability to hire or re-hire employees[154] - The company employs 86 people as of March 31, 2023, with a focus on maintaining good employee relations[133] Financial Obligations and Compliance - As of March 31, 2023, the Company was not in compliance with the required debt service coverage ratio, with an outstanding term loan amount of $3,461,000 and a line of credit balance of $1,540,000[158] - The total undiscounted lease payments as of March 31, 2023, amounted to $6,668,000, with a present value discount of $1,910,000, resulting in total lease liabilities of $4,758,000[162] - The Company had purchase obligations of $822,000 as of March 31, 2023, down from $1,105,000 in 2022, with a minimum purchase agreement expiring in April 2026[163] Earnings and Compensation - For the fiscal year ended March 31, 2023, the basic and diluted loss per share was $(0.55), compared to a basic income per share of $0.35 in 2022[172] - Compensation expense under the profit-sharing plan for fiscal year 2023 was approximately $0, compared to $121,000 in 2022[173] - Cost of sales for contract extraction and R&D services for the year ended March 31, 2023, was $441,000, slightly up from $439,000 in 2022[175] Stock and Tax Matters - The Company granted 50,000 stock options at a weighted average exercise price of $3.43 during the fiscal year ended March 31, 2023[167] - Nonvested restricted stock units at March 31, 2023, totaled 70,334 shares, with a weighted average price of $3.04[169] - The Company had net operating loss carryforwards available to offset future federal income tax, although specific amounts were not detailed[180] - The enactment of the CHIPS Act did not result in any material impact on the Company's income tax provision for fiscal year 2023[177] Intellectual Property - The company has registered trademarks in the U.S. and some foreign markets, which are important for product marketing[144]